...
首页> 外文期刊>Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia >Clinical outcome of severe head injury using three different ICP and CPP protocol-driven therapies.
【24h】

Clinical outcome of severe head injury using three different ICP and CPP protocol-driven therapies.

机译:使用三种不同的ICP和CPP方案驱动的疗法治疗严重的颅脑损伤。

获取原文
获取原文并翻译 | 示例
           

摘要

In the past 5 years, cerebral perfusion pressure (CPP) management has become the standard in the treatment of severe head injuries. Guidelines published in 2000 suggest that CPP should be at least 70 mmHg; however, there is still debate about the optimal CPP. The purpose of the present study was to evaluate the effectiveness of these three widely used therapies: (i) intracranial pressure (ICP) targeted; (ii) CPP-targeted with CPP >70 mmHg; and (iii) modified CPP-targeted (mCPP) therapy with CPP >60 mmHg. The clinical procedures, complications and outcomes of patients in the different groups were compared. Data, including patient age, sex, initial Glasgow Coma Scale, ICP, CPP, fluid status, amount of mannitol and vasopressor used, daily fluid intake and output, complications and clinical results, were collected from 213 patients with severe head injuries over a 12-year period. Patients were categorized into three groups (ICP, CPP, mCPP) according to the treatment protocol used. Retrospective data collection was performed by chart review. The mortality rate was 28.6%, 14.3% and 13.5% in the ICP, CPP, and mCPP groups, respectively. Highest intake/output ratio, amount of vasopressor used and pulmonary complications were seen in the CPP patients. The mCPP patients showed the best clinical outcome and lowest complication rate. Although CPP-targeted therapy is the most recommended therapeutic protocol, our data show that patients treated with modified CPP-target therapy with CPP >60 mmHg have better clinical outcomes and fewer complications.
机译:在过去的5年中,脑灌注压(CPP)管理已成为严重颅脑外伤治疗的标准。 2000年发布的指南建议CPP至少应为70 mmHg;但是,关于最佳CPP仍有争议。本研究的目的是评估这三种广泛使用的疗法的有效性:(i)靶向颅内压(ICP); (ii)以CPP> 70 mmHg为目标的CPP; (iii)CPP> 60 mmHg的改良CPP靶向(mCPP)治疗。比较了不同组患者的临床程序,并发症和结局。数据收集自213例12岁以上严重颅脑损伤患者的数据,包括患者年龄,性别,初始格拉斯哥昏迷量表,ICP,CPP,体液状态,甘露醇和升压药的使用量,每日体液摄入量和输出量,并发症和临床结果。年期间。根据使用的治疗方案,将患者分为三组(ICP,CPP,mCPP)。回顾性数据收集通过图表审查进行。 ICP,CPP和mCPP组的死亡率分别为28.6%,14.3%和13.5%。在CPP患者中观察到最高的进/出比例,使用的血管加压药量和肺部并发症。 mCPP患者表现出最好的临床结果和最低的并发症发生率。尽管以CPP为靶点的治疗是最推荐的治疗方案,但我们的数据表明,以CPP> 60 mmHg的改良CPP靶点治疗的患者具有更好的临床疗效和更少的并发症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号